Background
==========

Gastric adenocarcinomas comprise one of the common types of cancers in Asian countries including Japan, being second only to lung cancer as to the number of deaths it causes. In spite of the recent development of diagnostic techniques, most gastric cancer patients are diagnosed at an advanced stage and have a very low five-year survival rate (less than 10%) \[[@B1]\]. This is partially due to a lack of specific and sensitive biomarkers for the diagnosis and monitoring of disease progress at an early stage, although some gastric tumor markers, including the carcinoembryonic antigen, have been used and are partly effective. As gastric carcinogenesis is a multistep process, comprehensive analysis is also required for individual cases, in which different molecular events occur in each carcinogenic process.

Recently, proteomic analysis was utilized to comprehensively examine protein expression in bodily fluids, tissues and cells \[[@B2]-[@B4]\]. This approach, as clinical proteomics, is very useful for identifying disease-associated proteins that show changes in expression and modification corresponding to a disease condition \[[@B5],[@B6]\]. These disease-related proteins are expected to be biomarkers for diagnosis and putative targeted proteins for treatment \[[@B7]-[@B9]\]. On the other hand, comprehensive analyses of transcriptomes in tumor tissues from various cancer patients using DNA microarrays and gene chips have been performed in recent years \[[@B10]\]. However, a lack of correlation between changes in mRNAs and carcinogenesis has been demonstrated, and quantitative and qualitative changes of post-translationally modified proteins as final gene products are considered to be more informative than those of mRNAs in tumor tissues for studying the molecular events in carcinogenesis. Proteomic studies for the identification of tumor-associated proteins in gastric cancer are increasing, and proteome databases for gastric tissues \[[@B11]\] and cell lines \[[@B12]\] have been constructed. Most of them concern specific proteins or antigens that reflect the chemo- and thermo-resistant properties of stomach cancer \[[@B13]-[@B15]\], and that are associated with *Helicobactor pylori*\[[@B16],[@B17]\]. In the present study, we performed comprehensive proteome analysis of tumor and nontumor tissues in Japanese patients with gastric carcinomas, and identified several proteins of which the expression levels are commonly altered in clinical cases. In particular, the expression of gastrokine-1 (GKN-1) was suggested to be under both transcriptional and translational control.

Results
=======

Protein separation and identification
-------------------------------------

Figure [1A](#F1){ref-type="fig"} shows an image overview of a typical master gel for a gastric tumor tissue. Around 200 protein spots stained with Coomassie brilliant blue (CBB) R-250 were well separated in the gels. The numbered spots in Figure [1B](#F1){ref-type="fig"} and [1C](#F1){ref-type="fig"} were excised from a gel, treated with trypsin and then subjected to liquid chromatography-electronic spray ionization tandem mass spectrometer (LC-ESI-MS/MS) analysis. Seventy-two of them representing 69 different protein species were identified. Table [1](#T1){ref-type="table"} lists all of the proteins identified through peptide matching with the Mascot search algorithm. The accuracy in protein profiling was evaluated as the score value (above 37).

![(A) An overview of a master 2D gel image for tumor tissue derived from a patient with a gastric adenocarcinoma. (B) and (C) The numbered protein spots were identified by LC-ESI-MS/MS and protein matching, as shown as enlarged figures.](1476-4598-5-75-1){#F1}

###### 

Protein profile detected in tumor tissue derived from a Japanese patient with a gastric adenocarcinoma.

  Spot No.   Accession number   Protein identification                                                Mass     S.C. (%)   pI     Score
  ---------- ------------------ --------------------------------------------------------------------- -------- ---------- ------ -------
  1          24308169           axonemal heavy chain dynein type 3                                    473776   0          6.04   37
  2          15010550           heat shock protein gp96 precursor                                     90309    7          4.73   62
  3          72222              heat shock protein 90-β                                               83584    14         4.97   176
  4          5729877            heat shock 70 kDa protein 8 isoform 1                                 71082    19         5.37   283
  5          38044288           gelsolin isoform b                                                    80876    5          5.58   63
  6          4826960            glutaminyl-tRNA synthetase                                            88655    1          6.71   44
  7          4501867            aconitase 2                                                           86113    10         7.36   231
  8          119717             ezrin                                                                 69470    7          5.94   75
  9          4557871            transferrin                                                           79280    9          6.81   97
  10         16507237           heat shock 70 kDa protein 5                                           72402    15         5.07   165
  11         24234686           heat shock protein 70 kDa protein 8                                   53598    16         5.62   160
  12         4885431            heat shock 70 kDa protein 1B                                          70267    11         5.48   143
  13         1082886            tumor necrosis factor type 1 receptor-associated protein TRAP-1       75694    13         8.43   288
  14         31542947           chaperonin, mitochondrial matrix protein P1, P60 lymphocyte protein   61187    13         5.7    299
  15         28592              serum albumin                                                         71316    23         6.05   292
  16         340219             vimentin                                                              53738    18         5.03   79
  17         4503729            similar to FK506-binding protein 4                                    49031    5          5.6    36
  18         32709              IFP53                                                                 53559    21         5.93   277
  19         4502643            chaperonin-containing TCP1, subunit6A (zeta 1)                        58444    6          6.23   79
  20         7106439            tubulin, β5                                                           50095    14         4.78   125
  21         37492              α-tubulin                                                             50810    13         5.02   94
  22         125604             pyruvate kinase, M2 isozyme                                           58447    5          7.95   234
  23         4557014            catalase                                                              59947    6          6.9    120
  24         4503483            eukaryotic translation elongation factor 2                            96246    4          6.41   56
  25         179279             ATP synthase β subunit                                                56861    5          5.39   59
  26         7657041            down-regulated in metastasis                                          320846   2          7.07   40
  27         4504169            glutathione synthetase, GSH synthetase                                52523    5          5.67   99
  28         12017952           GE36                                                                  73327    2          5.2    37
  29         34234              laminin-binding protein                                               31888    12         4.84   51
  30         16359158           actin, beta                                                           42078    14         5.29   171
  31         6635125            KIAA0284 protein                                                      161473   2          6.36   47
  32         5803225            14-3-3 epsilon                                                        29326    8          4.63   49
  33         4504707            inositol polyphosphate-4-phosphatase, type II, 105 kD                 105749   1          5.87   37
  34         35038601           hypothetical protein DKFZp761A078                                     74864    2          7.27   47
  35         12017952           GE36                                                                  73327    1          5.2    38
  36         4505877            plectin 1 isoform 1                                                   520111   1          5.57   44
  37         38158018           centrosomal protein 1, centriole associated protein, centriolin       269874   1          5.44   39
  38         30157438           CTD-binding SR-like protein rA9                                       180240   1          9.15   41
  39         4503471            eukaryotic translation elongation factor 1 α1                         50451    12         9.1    191
  40         4757810            ATP synthase                                                          59828    17         9.16   178
  41         693933             2-phosphopyruvate-hydratase α-enolase                                 47421    22         7.01   240
  42         123576             47 kDa heat shock protein precursor                                   46352    14         8.27   177
  43         5032069            splicing factor 3b, subunit 4                                         44414    3          8.54   58
  44         4503471            eukaryotic translation elongation factor 1 α1                         50451    4          9.1    47
  45         5921789            citrate synthase, mitochondrial precursor                             51959    12         8.13   114
  46         4505763            phosphoglycerate kinase 1                                             44985    14         8.3    87
  47         4504069            aspartate aminotransferase 2 precursor                                47844    6          9.14   52
  48         7669492            glyceraldehyde-3-phosphate dehydrogenase                              36201    13         8.57   49
  49         4757756            annexin A2                                                            38808    9          7.57   87
  50         6648067            malate dehydrogenase, mitochondrial precursor                         35965    7          8.92   60
  51         5031857            lactate dehydrogenase A                                               36950    6          8.44   43
  52         238427             porin 31 HM                                                           30737    29         8.63   124
  53         5174447            guanine nucleotide-binding protein                                    35511    8          7.6    65
  54         34740329           heterogeneous nuclear ribonucleoprotein A3                            39799    7          9.1    43
  55         4504983            galectin-3                                                            26229    12         8.58   42
  56         4504447            heterogeneous nuclear ribonucleoprotein A2/B1 isoform A2              36041    7          8.67   40
  57         86901              ATP-dependent DNA helicase RAP30/74 chain RAP30                       26350    3          9.46   41
  58         230445             carbonic anhydrase I                                                  28903    12         6.44   67
  59         455739             carbonic anhydrase II                                                 29285    8          6.87   82
  60         26892090           beta-globin chain variant                                             16101    40         7.86   121
  61         34709              manganese superoxide dismutase                                        24891    10         8.35   111
  62         4507645            triosephosphate isomerase 1                                           26938    17         6.45   47
  63         38488935           foveolin precursor                                                    20546    16         5.65   95
  64         478813             nonhistone chromosomal protein HMG-1                                  25139    13         5.41   60
  65         2204207            glutathione S-transferase                                             23595    34         5.43   73
  66         178755             proapolipoprotein                                                     28944    8          5.45   103
  67         37267              transketolase                                                         68435    4          7.9    59
  68         189998             M2-type pyruvate kinase                                               58447    10         7.95   157
  69         825605             glutathione S-transferase                                             25650    10         8.51   65

These proteins can be classified into several categories based on their functions, including cytoskeleton proteins, stress-related and chaperoning proteins, acute-phase proteins, glycolytic enzymes, enzymes involved in metabolism and cell proliferation, tumor suppressor proteins and stomach-specific proteins.

Common alterations of protein expression between tumor and nontumor tissues in gastric cancer patients
------------------------------------------------------------------------------------------------------

Diverse alterations in proteomes were detected between tumor and nontumor tissues from the same patients. As shown in Figure [2](#F2){ref-type="fig"}, the several common alterations were observed among in five Japanese gastric cancer patients (Cases A to E). Manganese superoxide dismutase (MnSOD), nonhistone chromosomal protein HMG-1 (HMG-1), phosphoglycerate kinase 1 (PGK-1), carbonic anhydrase I and II (CA I and II), foveolin precursor FOV (gastrokine-1), aspartate aminotransferase 2 precursor (AST), and glutathione S-transferase (GST) exhibited common changes in expression between tumor and nontumor tissues, including among the identified proteins. The protein expression of MnSOD and HMG-1 was demonstrated to be up-regulated in tumor tissues compared to in nontumor tissues. On the other hand, the CA I and II, FOV, AST and GST proteins were revealed to be down-regulated in tumor tissues. The fold changes in the expression of these proteins relative to that of GAPDH are summarized in Table [2](#T2){ref-type="table"}. The most remarkable decrease was shown in the level of FOV in all cases. The degree of the decrease in GST protein expression was almost the same as that in FOV (Cases B, D, and E), although one was not observed in the other two cases. On the other hand, the increase in HMG-1 was marked in three cases (A, C, and D), although such a difference in expression was not observed in the other two cases. MnSOD exhibited a tendency to increase in the tumor tissues of three patients (Cases A, C, and D), but a relative decrease was also observed in Case B. As for PGK-1, a significant relationship between fold changes in protein expression and the pathological grading of tumors was hardly observed.

![Detailed alteration patterns of proteins. (A) Nontumor and (B) tumor proteins including CAI (No.58), CAII (No.59), MnSOD (No.61), FOV (No.63), HMG-1 (No.64), and GST (No.65). (C) Nontumor and (D) tumor proteins including PGK-1 (No.46), AST (No.47), and GST (No.69). GAPDH, circled, was used as a reference protein.](1476-4598-5-75-2){#F2}

###### 

Fold changes in protein expression between nontumor and tumor tissues derived from five patients with gastric adenocarcinomas.

  Protein   Case A   Case B   Case C   Case D   Case E
  --------- -------- -------- -------- -------- --------
  CA I      -6.5     -1.6     -3.3     -4.3     -2.6
  CA II     -2.6     -1.3     -26      -4.3     -13
  FOV       -13      -13      -26      \*       -26
  MnSOD     +1.7     -2.6     +6.5     +1.4     +1.1
  HMG-1     +13      \*       +3.7     +13      \*
  PGK1      +1.6     +1.1     -1.2     +2.6     -1.4
  AST       -13      -1.6     -6.5     -3.7     -2.6
  GST       \*       -26      \*       -13      -13

CA I, carbonic anhydrase I.

CA II, carbonic anhydrase II.

FOV, foveolin precursor.

MnSOD, manganese superoxide dismutase.

HMG-1, nonhistone chromosomal protein.

PGK1, phosphoglycerate kinase 1.

AST, aspartate aminotransferase 2 precursor.

GST, glutathione S-transferase.

\*, not determined.

RT-PCR analysis
---------------

By RT-PCR, changes in mRNA expression in tumor and nontumor tissues derived from gastric cancer patients were analyzed for proteins that exhibited alterations in protein expression, including FOV, MnSOD and HMG-1. As shown in Figure [3](#F3){ref-type="fig"}, FOV mRNA was significantly decreased in tumor tissues in four at all patients (Cases A, B, C, and E), while it was not detected in either nontumor or tumor tissues from the other patient (Case D). On the other hand, MnSOD mRNA was markedly increased in four patients (Cases B, C, D, and E), although little difference in the mRNA level between nontumor and tumor tissues in Case A was detected. However, a relationship between HMG-1 mRNA expression and the pathological phenotypes of tumors was hardly observed.

![Comparison of mRNA expression of proteins possibly associated with carcinogenesis between nontumor and tumor tissues derived from five patients with gastric adenocarcinomas (cases A to E) by RT-PCR. N and T indicate nontumor and tumor tissues, respectively.](1476-4598-5-75-3){#F3}

Discussion
==========

In this study we performed proteomic analysis of tumor and nontumor tissues derived from Japanese gastric adenocarcinoma patients. Sixty-nine different proteins in the tumor tissue from a gastric cancer case were identified by 2D-EP and LC-ESI-MS/MS, which included stress proteins, Hsp70, Hsp90 and chaperonine-containing TCP1 (CCT), for self-protection; glycolytic enzymes, triose phosphate isomerase 1, α-enolase and PGK-1, for the growing energy requirement; cytoskeletal proteins, ezrin, gelsolin isoform b and vimentin; proteins involved in cell differentiation and proliferation, galectin-3 and transferrin; and proteins exhibiting putative tumor suppressor activity, FOV. Many of these proteins have been reported to be associated with the tumorigenesis of gastric adenocarcinomas involving multiple steps and factors \[[@B18],[@B19]\].

We also demonstrated that the expression levels of several proteins in tumor tissues were commonly altered in five Japanese patients with gastric adenocarcinomas, compared to those in nontumor tissues. A common increase in protein expression in tumor tissues occurred for MnSOD, HMG-1 and PGK-1, whereas a common decrease in tumor tissues occurred for FOV, GST and AST.

Superoxide (O~2~^-^), a free radical, is essential for the anti-microbial action of granulocytes and monocytes. Superoxide dismutase (SOD) rapidly removes the excess amount of superoxide produced in the stress and biological reactions *in vivo*through catalysis of the conversion of superoxide with H^+^to H~2~O~2~and O~2~. MnSOD, one of the SODs, is located in mitochondria and contributes to the protection of mitochondrial DNA from damage. It has been reported that enhanced expression of MnSOD in progressive gastric cancer should be related to the 5-year survival rate after surgery \[[@B20]\] and sensitivity to chemotherapy \[[@B21]\]. In this study, protein expression of MnSOD was up-regulated in 4 of 5 gastric cancer patients, suggesting a self-protecting response. On the other hand, the up-regulation of MnSOD in tumor tissues has been considered to interfere with effective chemotherapy based on radical production, which may cause a decrease in sensitivity to anti-cancer drugs and determine the severity of the cancer.

HMG-1 regulates the transcription of various genes and the structural stabilization of chromosomes as a DNA-binding protein. HMG-1 has been reported to be associated with carcinogenesis and metastasis in colorectal and breast cancer \[[@B22]\].

Transcriptional up-regulation of HMG-1 in gastric cancer has also been demonstrated \[[@B23]\]. Expression of HMG-1 in tumor tissues was suggested to be related to resistance to cisplatin \[[@B24]\]. We demonstrated here an increase in this protein in three cases.

GST is a drug-metabolizing enzyme that catalyzes the conjugation of reduced glutathione to drugs and metabolites, and also contributes to the detoxification of carcinogens. Therefore, a decrease in the activity may be a risk factor for carcinogenesis. Infection by Helicobacter pylori has been reported to cause a decrease in GST expression \[[@B25]\], suggesting that a decrease in GST activity might be a cause of gastric carcinogenesis. In this study, a decrease in GST protein expression was observed in three cases. A decrease in GST protein expression may be utilized as a biomarker for the diagnosis of gastric tumors.

AST is an aminotransferase that acts on amino acids and α-keto acid, that is distributed widely in human organs. AST is released into the blood stream due to enhanced permeability and destruction of tissues. A elevated concentration of AST protein has been reported in the blood of patients with hepatitis, malignant tumors including hepatomas, and leuchemia. Gene expression of GST has also been demonstrated to be up-regulated in colorectal tumor tissues \[[@B26]\]. However, a decrease in AST protein expression was commonly observed in all tumor tissues derived from the present five patients with gastric adenocarcinomas. Further study should be performed to elucidate whether a decrease in the AST protein is specifically observed in gastric tumor tissues or not.

Elevated expression of PGK-1, which is one of the enzymes in the glycolytic pathway and which catalyzes the dephosphorylation of 1,3-bisphosphoglycerate to produce ATP, has been observed in many malignant tumor tissues that are dependent on ATP as a major energy source. Solid tumors are thought to need the overproduction of ATP to maintain the enhanced proliferation. The up-regulation of glycolytic enzymes, including PGK-1 in lung cancer \[[@B27]\] and M2-type pyruvate kinase in colorectal cancer \[[@B28]\], has been reported and suggested to be useful for cancer screening. However, in the present study, a significant relation between PGK-1 protein expression and the phenotypes of gastric adenocarcinomas was hardly detected. Therefore, PGK-1 was considered to be not suitable for the diagnosis of gastric cancer.

Carbonic anhydrases (CAs) are zinc-containing enzymes that are distributed widely in various organs and that comprise a large family including CA-I to CA-IX. They catalyze the hydration of CO~2~for intermediate metabolism, and maintain the pH and ion equilibrium in the body. So far a direct relationship has been demonstrated between malignant transformation and protein expression for CAs I through VII \[[@B29]\]. Two earlier studies revealed that the expression of both CA-I and CA-II was significantly reduced in colorectal tumors compared to in normal colorectal epithelia or mucosae \[[@B30]\]. Another report presented results showing that reduced expression of CA-I and CA-II was correlated with the biological aggressiveness of colorectal cancer and synchronous distant metastasis \[[@B31]\]. As suggested previously \[[@B32]\], gastric and colorectal carcinomas may share a similar mechanism of cell proliferation and mucosal malignancy, and may become a biomarker for these carcinomas, because common decreases in the protein expression of CA-I and CA-II were also observed in this study.

FOV, which is identical to a stomach-specific 18-kDa antrum mucosa protein! (AMP-18) \[[@B33],[@B34]\], GKN1 \[[@B35]\], and trefoil factor interactions(z) (TFIZ) \[[@B36]\], was demonstrated to be dramatically down-regulated or absent in the gastric adenocarcinoma patients in this study. The human AMP-18 and human carcinoantigenic CA11 gene product, which encodes an amino acid sequence that differs from that of AMP-18 in only a single residue \[[@B37],[@B38]\], function as secreted growth factors partly responsible for maintaining a normal functional gastric epithelium \[[@B33]\]. Both AMP-18 and the CA11 gene product have been reported to be intensively expressed in normal stomach tissue but not in most gastric cancers \[[@B33],[@B37],[@B38]\]. Immunohistochemical studies demonstrated that AMP-18 appears to be present in mucosal epithelial cells of the normal human gastric antrum and duodenum \[[@B33]\]. Recently, TFIZ was demonstrated to act as a growth regulator of gastric epithelial cells through the formation of a heterodimer with trefoil factor 1 (TFF1) \[[@B36]\]. Our present data further confirmed the high expression of FOV in nontumor gastric tissues and the significant suppression of the protein in gastric adnocarcinomas, indicating that FOV play roles in the maintenance of normal differentiation of epithelial cells and tumor suppression but not in tumor tissues. Furthermore, we demonstrated that transcription of FOV mRNA was also commonly down-regulated in gastric cancer patients, indicating that a marked decrease in FOV protein was caused by suppression of FOV gene expression. Furthermore, in one patient the protein was not detected in nontumor tissues, suggesting that the expression level of FOV protein in individuals may determine the gastric adenocarcinoma phenotype. Accordingly, the expression level of FOV as a biomarker may be informative for the assessment of gastric cancer.

Conclusion
==========

Protein profiling of tumor and nontumor tissues derived from Japanese patients with gastric adenocarcinomas was performed using 2D-EP and LC-ESI-MS/MS. The identified proteins included molecular chaperones, energy-producing enzymes, cytoskeletal proteins, and so on. Common protein alterations were detected in the gastric cancer patients. Protein expression of MnSOD and HMG-1 was up-regulated while that of GST, AST and FOV was down-regulated in gastric tumor tissues. A correlation between the alteration of these proteins and their transcriptional expression in gastric cancer was hardly observed in this study, except for in the case of FOV. Both the protein and gene expression of FOV, a stomach-specific secretory growth factor for normal gastric epithelial cells, was markedly down-regulated in tumor tissues derived from Japanese patients with gastric adenocarcinomas. Monitoring of the expression levels of this stomach-specific protein in clinical samples may provide useful information for the diagnosis of gastric cancer as a specific biomarker and for better understanding of gastric carcinogenesis.

Methods
=======

Materials
---------

DNase I, RNase A, 2-mercaptoethanol (2-ME), glass beads (212--300 μm), Nonidet P-40, acrylamide, *N,N,N\',N\'*-tetramethylenediamine (TEMED), sodium dodecylsulfate (SDS), iodoacetamide and dithiothreitol (DTT) were purchased from Sigma (St. Louis, MO). Agarose for isoelectronic focusing (IEF), and Pharmalyte pI 3--10, 4--6.5 and 8--10.5 were from Amersham Bioscience (Piscataway, NJ). Trypsin (sequencing grade) was from Roche (Manheim, Germany). Phenylmethylsulfonyl fluoride (PMSF), thiourea, sorbitol, sodium pyrophosphate, ammonium persulfate, D,L-aspartic acid, trichloroacetic acid, sulfosalicylic acid dihydrate, acetic acid, acetonitrile, formic acid and trifluoroacetic acid (TFA) were from Wako Pure Chemicals (Osaka, Japan). Urea was from Katayama Chemicals (Osaka, Japan). Pepstatin A and leupeptin were from the Peptide Institute (Osaka, Japan). NH~4~HCO~3~and N,N\'-methylenebisacrylamide were from Nacalai Tesque (Kyoto, Japan). CBB R-250 was from ICN Biomedicals Inc. (Aurora, OH). Molecular mass standards were from APRO Science, Inc. (Tokushima, Japan). TRIZOL reagent was from Life Technologies (Frederick, MD). Oligo(dT)12--18 primer, deoxynucleotides (dNTPs), and RNaseOUT were from Invitrogen (Carlsbad, CA). M-MLV reverse transcriptase and Taq DNA polymerase were from Promega (Madison, WI).

Tissues and sample preparation
------------------------------

Primary gastric adenocarcinomas and adjacent nontumor mucosae were collected on gastrectomy and provided by the Dept. of Surgery, Graduate School of Medicine, The University of Tokushima, Tokushima, Japan. The research was carried out in accordance with the Declaration of Helsinki of the World Medical Association, and was approved by the ethical committee of the University of Tokushima. Informed consent was also given by all of the patients who provided the clinical samples. Tissues were frozen in a dry ice-methanol bath as soon as possible after dissection and stored in a deep freezer (-80°C) before use. For mRNA analysis, tissues were first immersed in RNAlater (Takara, Tokyo, Japan) before freezing. Detailed clinicopathological data including the tumor stage (according to the AJCC system), site and differentiation, and histological data on the tissue samples are listed in Table [3](#T3){ref-type="table"}. None of these cases were classified in the scirrhous type category, and tumor tissue was clearly distinguishted from non-tumor one in each case. For two-dimensional gel electrophoresis (2D-EP), protein extraction from tissues was carried out by the following procedure. Frozen blocks (20--30 mg wet weight) were homogenized with a plastic pestle (Toyobo, Tokyo, Japan) in the presence of glass beads in 10 vol/wet weight of dialysis buffer comprising 5 M urea, 1 M thiourea, 10 mM NaPPi, 1.67 μL/mL 2-ME, 0.005% DNase I, 0.05 mg/ml RNase A, 20 μM leupeptin, 1 mM EDTA, 2 mM PMSF and 20 μM pepstatinA, and then centrifuged at 50,000 rpm for 30 min at 4°C (Beckman -Coulter, Fullerton, CA). The resultant supernatant was used as the tissue extract. Protein concentrations were determined with a Bradford protein assay kit (Bio-Rad, Hercules, CA) using bovine gamma-globulin as a standard.

###### 

Clinical features of the patients with gastric adenocarcinomas.

  Case   Age   Sex      Location^a^   Grade^b^   Stage   
  ------ ----- -------- ------------- ---------- ------- ----------
  A      63    Male     UM            G3         IIIA    T2N2M0H0
  B      68    Female   L             G2         II      T2N2M0
  C      76    Male     ML            G2         IV      T4N3M0
  D      78    Female   L             G2         III     T2N0M0H0
  E      77    Male     ML            G2         II      T2N1M0

^a^U: upper, M: middle, L: lower

^b^G2: moderately differentiated, G3: poorly differentiated.

Two-dimesional gel electrophoresis
----------------------------------

2D-EP was carried out as described previously \[[@B39]\]. The first-dimensional isoelectric focusing was performed in an 1% (w/v) agarose gel (ϕ 2.6 × 180 mm) with a pH 3--10 gradient at 700 V for 18 hr at 4°C, and the second-dimensional SDS gel electrophoresis was performed with a 5--15% (w/v) acrylamide gradient (*M*r range, 6--200 kDa) in a standard slab gel (20 × 13 cm) at 15 mA for 3 h, and then at 70 mA for 2 h at room temperature. Gels were stained with CBB R-250.

Protein samples (500 μg) extracted from the tumor center and surrounding histologically normal mucosa were subjected to 2D-EP and run in pairs side by side.

Some of the stained spots were excised from the 2D-gel, in-gel digested with trypsin and then subjected to LC-ESI-MS/MS analysis as described previously \[[@B40]\]. The peptide mixture was separated with a reversed phase nanoLC system (Famous, Swichos II, Ultimate, LC Packings, Sunnyvale, CA). The eluted peptides were sprayed directly into an ESI mass spectrometer (Esquire3000 Plus, Bruker-Daltonics, Fremont, CA).

A large volume of MS/MS data was acquired with DataAnalysis 3.1 software (Bruker-Daltonics), converted to text files listing the mass values of the parent ions, and intensities and masses of fragment ions, and then processed with the MASCOT algorithm (Matrix Science Ltd, London, U.K.) to assign peptides in the NCBI non-redundant sequence database using a taxonomic restriction, \'human\'. The database search was performed with the parameters described by Yoshimura et al. \[[@B40]\].

Image analysis and MS peptide sequencing
----------------------------------------

Image acquisition and analysis were performed with Molecular Imager FXProPlus (Bio-Rad) and ImageMaster software (Bio-Rad). Comparisons were made between gel images of tumor and matched nontumor samples pair by pair. Normalized volume differences were statistically calculated for all five cases. The content of glyceraldehyde 3-phosphodehydrogenase (GAPDH) protein was used as a reference to evaluate the fold alteration of protein expression between tumor and matched nontumor tissues as the levels of GAPDH mRNA and protein were not changed between tissues derived from patients. Consistently and significantly different spots were selected for analysis by LC-ESI-MS/MS. Protein spots!were cut out from gels in small pieces, and subjected to in-gel tryptic digestion overnight \[[@B40]\]. Peptide mass spectra were recorded, and parameters for spectra acquisition were used as stated previously \[[@B40]\]. Accuracy in database protein matching using Mascot Search \[[@B41]\] was judged as a score over 37, which was obtained in most of the analyses.

RNA isolation and RT-PCR analysis
---------------------------------

Tumor and matched nontumor samples (approx. 50 mg wet weight) were minced, and then homogenized manually in 1 ml of TRIZOL reagent (Invitrogen) on ice. RNA was isolated without DNase I treatment according to the manufacturer\'s protocol. Briefly, 0.2 ml of CHCl~3~was added to the homogenate, followed by centrifugation at 20,600 × g for 15 min. An equal volume of 2-propanol was added to the resultant supernatant to precipitate RNA. After centrifugation, the pellet was rinsed with 75% ethanol/diethylpyridylchloride (DEPC)-treated water, followed by drying. The pellet was dissolved in an appropriate volume of DEPC-treated water as the total RNA fraction. For reverse transcription (RT), 2 μg of RNA from each sample was transcribed at 37°C for 1 h in the presence of 200U of Molony leukemia virus reverse transcriptase (Promega), oligo(dT)~12--18~primer, 0.5 mM dNTPs and 50U of RNaseOUT. The PCRs for carbonic anhydrase-I and II, glutatione-S-transferase, FOV, and GAPDH were performed within a linear range of amplification using the selected primer set and conditions, and expected size of products, as summarized in Table [4](#T4){ref-type="table"}. The PCR products were analyzed by 1.5% agarose gel electrophoresis and stained with ethidium bromide.

###### 

Primer sets used for RT-PCR analysis.

  Primers               Primer sequences
  --------- ----------- ---------------------------------------
  MnSOD     sense       5\' - acgcggcctacgtgaacaacctgaa - 3\'
            antisense   5\' - aaccccaacctgagccttggacacc - 3\'
  HMG-1     sense       5\' - cgggaggagcataagaagaagcacc - 3\'
            antisense   5\' - caatggacaggccaggatgttctcc - 3\'
  GAPDH     sense       5\' - gtcatccatgacaactttgg - 3\'
            antisense   5\' - tgctgtagccaaattcgttg - 3\'

MnSOD, manganese superoxide dismutase.

HMG-1, nonhistone chromosomal protein.

GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Abbreviations
=============

2D-EP, Two-dimensional gel electrophoresis; 2-ME, 2-Mercaptoethanol; AMP-18, Antrum mucosa protein-18; AST, Aspartate aminotransferase 2 precursor; CA I and II, Carbonic anhydrase I and II; CAs, Carbonic anhydrases; CBB, Coomassie brilliant blue; CCT, Chaperonine-containing TCP1; DEPC, Diethylpyridylchloride; dNTPs, Deoxynucleotides; DTT, Dithiothreitol; FOV, Foveolin precursor (gastrokine-1); GAPDH, Glyceraldehyde 3-phosphodehydrogenase; GKN1, Gastrokine-1; GST, Glutathione S-transferase; HMG-1, Nonhistone chromosomal protein HMG-1; IEF, Isoelectronic focusing; LC-ESI-MS/MS, Liquid chromatography-electronic spray ionization-tandem mass spectrometer; MnSOD, Manganese superoxide dismutase; PGK-1, Phosphoglycerate kinase 1; PMSF, Phenylmethylsulfonyl fluoride; RT, Reverse transcription; SDS, Sodium dodecylsulfate, SOD, Superoxide dismutase; TEMED, *N,N,N\',N\'*-Tetramethylenediamine; TFA, Trifluoroacetic acid; TFF1, Trefoil factor 1; TFIZ, Trefoil factor interactions(z).

Competing interests
===================

The author(s) declare that they have no competing interests.

Authors\' contributions
=======================

TY mainly carried out the molecular studies, participated in the proteomic determination and RT-PCR analysis. YK carried out the proteomic studies, partly participated in the proteomic determination. YY supported the proteomic studies by TY. YT partly participated in the RT-PCR for gastric cancer-related protein. NT parly participated in the proteomic determination. HO carried out the operation of gastric cancer patiens, participated in providing the cancer tissues. AU carried out the operation of gastric cancer patients, participated in providing clinical information. TY supported the proteomic studies and advised the methods. KI conceived of the study, and participated in its design and coordination. All authors read and approved the final manuscript.

Acknowledgements
================

This work was supported by grants from Taiho Pharmaceutical Co., Ltd. and the Suzuken Memorial Foundation.
